PIK3CG and endometrial carcinoma: Besides Type I, PI3K/AKT/mTOR pathway dysregulation also contributes to the development of Type II endometrial carcinoma, as the pathway has been shown to interact with p53 signaling in uterine serous carcinoma cells.